About
Scala Biodesign develops cutting-edge computational protein design solutions to address complex protein development challenges in the pharmaceutical, chemical, diagnostics and food sectors. Antibodies, vaccines and sustainable chemical manufacturing demand proteins that meet exceptionally stringent requirements in activity, shelf-life and safety. Yet, traditional methods for protein engineering are costly, lengthy and failure-prone. Scala’s one-shot approach dramatically accelerates the development process, increases success rates and slashes R&D efforts, thereby enabling its partners to pursue challenging projects that were previously beyond their reach. Scala has partnered with some of the largest pharma and chemical corporations worldwide and its technology has successfully overcome development challenges that confounded expert teams for years.
Scala, under the leadership of Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), leverages the technologies they developed in the group of Prof. Sarel Fleishman (Chief Scientist) which was licensed from the Weizmann Institute of Science. Scala is positioned to become the primary destination for corporations venturing into new protein-based product development.
Funding history · 2 rounds · $21.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Scala Biodesign founded and where is its headquarters located?
- Scala Biodesign was founded in March 2022 and is headquartered in Tel Aviv-Yafo, Israel.
- What is Scala Biodesign's primary focus?
- Scala Biodesign specializes in computational protein design solutions for complex protein development challenges in the pharmaceutical, chemical, diagnostics, and food sectors.
- What was Scala Biodesign's initial funding round?
- In March 2022, Scala Biodesign secured a Seed round of $5.5 million, led by TLV Partners.
- What was Scala Biodesign's most recent funding round?
- In March 2026, Scala Biodesign completed a Series A round, raising $16 million. Lead investors included Grove Ventures.
- What is the total amount of funding Scala Biodesign has raised to date?
- Scala Biodesign has raised a total of $21.5 million across its funding rounds. For a full financing history, refer to startupim.
- Who are the key founders of Scala Biodesign?
- Scala Biodesign was founded by Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO).
- From which institution did Scala Biodesign license its core technology?
- Scala Biodesign licensed its core technologies from the Weizmann Institute of Science, developed in the group of Prof. Sarel Fleishman, who serves as Chief Scientist.
- How many employees does Scala Biodesign currently have?
- Scala Biodesign currently has 22 employees.
- What is Scala Biodesign's current funding stage?
- Scala Biodesign is currently in its Series A funding stage.